1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Jonathan Poland
Jonathan Poland
Articles (453)  | Author's Website |

Will 2019 Be Gilead's Turnaround Year?

With a new pipeline of drugs expected over the next two years, growth is coming back again

November 20, 2018 | About:

Barring some miracle new drug breakthrough announcement, Gilead (NASDAQ:GILD)'s 2018 has been one to forget. The drugmaker turned HIV into a manageable chronic ailment and is developing a cure for hepatitis C. In the annals of history, Gilead will be remembered by the future robot overlords as prolonging human life long enough to create the singularity.

While I'm only half joking, Gilead has done wonderful things for the health of society. In the process, it saw sales go from $5 billion to over $32 billion in 2015, slipping back down to $22 billion in the last 12 months. And, while the company is still profitable, generating $1.5 billion net year-to-date, that is down from the massive $18 billion in net income it saw in 2015.

Despite the Hepatitis C segment of Gilead's business in decline (sales dropped 15% in the third quarter), the overall product pipeline is strong with six new drugs in Phase 3 and 17 in Phase 2 of FDA approval. In fact, just yesterday the China National Medical Products Administration (NMPA) approved Gilead's Vemlidy, a once-daily treatment for chronic hepatitis B in adults and adolescents. There are an estimated 130 million carriers and 30 million chronically infected with HBV in China.

799038814.png

Is Gilead worth $90 billion?

The profit centers derived from the company's HIV and Hepatitis C drugs are virtually unmatched. On the HIV front, Gilead's next generation of HIV drugs, Genvoya and Biktarvy, will offer better long-term safety. While sales of its Hepatitis C drugs, Sovaldi and Harvoni, may have peaked at more than $19 billion in 2015, the lower sales are expected to lead to a more stable market -- one that Gilead and AbbVie control.

In 2020, Gilead is expected to have multiple immunology and cancer drugs on the market or close to market. The company also has already gained approval for cancer treatments in Europe. In addition, as its drugs go off patent, especially the Hep C ones, the company has already started making its own generics. Investors have pushed this stock too far down.

Competitors Amgen and AbbVie are priced between 40% and 50% higher than Gilead and have taken slower growth trajectories. Gilead is not just fading away. If Gilead's stock was priced on par with Amgen, the cap would rise back into the $120 billion to $125 billion range, a 40% pop for shareholders. This could easily happen by the end of 2020, which is just 25 months away.

Disclosure: I am not long/short any stock mentioned in this article.

Read more here: 

Jerome Dodson Comments on Gilead Sciences

Risk-Reward With Gilead Sciences

10 Undervalued Stocks for the Enterprising Investor - August 2018

About the author:

Jonathan Poland
I used to manage money. I still publish my thoughts on stocks here on GuruFocus, mainly on big cap companies. I rarely write about stocks that I own. Thank you for reading.

Visit Jonathan Poland's Website


Rating: 0.0/5 (0 votes)

Comments

brightluisa12
Brightluisa12 - 1 week ago    Report SPAM

I am really happy that i have been cured from (HEPATITIS B VIRUS) with the herbal medicine of Dr Aza, i have been suffering from this disease without any solution until i came across the email of this doctor who have cure so many people with his herbal medicine, i also choose to give him a chance to help me and my husband, he told me what to do and i kindly did it, and he gave us his herbal medicine and direct me on how to use it, i also follow his instructions for use and he ask us to go for a check up after 1 week and 4days which i did, to my greatest surprise our result came out as negative, we are really happy that there is someone like this doctor who is ready to help anytime any day. To all the readers and viewers that is doubting this testimony stop doubting it and contact this doctor if you really have one and see if he will not actually help you. i am not a stupid woman that i will come out to the public and start saying what someone have not done for me and i know that there are some people out there who are really suffering and hurting just because of these diseases so you can mail him on [email protected] or whatsApp his number on +2349053099479

Please leave your comment:


Performances of the stocks mentioned by Jonathan Poland


User Generated Screeners


DANGORDONPE<16
DANGORDONROE ROC 10YR
DANGORDONROC10YR
DANGORDONROE10YR
Praveen ChawlaDividend Achievers
hiroller8Super Stocks
DBrizanCDN2019feb17
curtisAsia xJxCNxIN
awilkinsonLynch
daleromanHigh Margin pe<15
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK